AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06663683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip thrust
Description: The subjects in Hip Thrust (HT) group will be instructed to perform low-load gluteus activation exercises, which included single-leg bridges, clamshells and quadruped hip extensions. One set of ten repetitions or steps will perform for each exercise. In this training program three stages which focused on enhancing hypertrophy and strength of the hip extensors in sequence. During the training period, the subjects will be instructed to maintain their usual daily activities and diet. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between the sessions. Hip thrust training 3 sets with 10 repetitions in each set and 2 minutes rest between each set.
Study NCT06663683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back squat
Description: In Back Squat (BS) resistance training the subjects starts with the standing position with the feet flat on the floor, the knees and hips in a neutral, extended anatomical position, and the spine in an upright position with preservation of its natural curves. The squat movement will begin with the descent phase as the hips, knee and ankles flex. A common instruction will be given to the subjects to descend until the top of the thigh is at least parallel with ground and the hip joint is at least level with or slightly below the knee joint. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between sessions. Back squat training 3 sets with 10 repetitions in each set \& 2 minutes rest between each set.
Study NCT05535166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: All participants enrolled will undergo surgical resection prior to treatment. The maximal resection that can be achieved without undue risk to the patient will be attempted, with decisions about feasibility and extent of resection left to the discretion of the neurosurgeon. In instances where an STR is the best extent of resection achieved prior to start of therapy, a second-look surgery may be performed between cycles of chemotherapy after discussion with the principal investigator.
Study NCT05535166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ommaya/VPS
Description: All participants enrolled on S-1 will undergo
Study NCT05535166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Route of administration: Intravenously (IV)
Study NCT05535166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Route of administration: Intravenously (IV)
Study NCT05535166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Route of administration: Intravenously (IV)
Study NCT05535166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Route of administration: Intravenously (IV)
Study NCT05535166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Route of administration: Intravenously (IV)
Study NCT05535166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Route of administration: Intravenously (IV)
Study NCT05535166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Route of administration: Intravenously (IV)
Study NCT05535166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Route of administration: subcutaneous (SQ)
Study NCT05535166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Route of administration: subcutaneous (SQ) or Intravenously (IV)
Study NCT05535166 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation
Description: All participants in stratum N will undergo craniospinal irradiation (CSI) with boost to the primary tumor site once they reach 36 months of age. The dose given is based on the molecular risk group and disease response to chemotherapy as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
Study NCT05535166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and Media Intervention
Description: Participants watch a 75-minute caregiver education video program and receive access to interactive games on a smartphone or tablet throughout the optional cognitive study.
Study NCT05535166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC, Educational and Media Intervention
Description: Standard-of-care (SOC) treatment during main cognitive study. After the one-year serial cognitive evaluation, participants will be offered participation in the cognitive study group I intervention.
Study NCT05840965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot muscle strengthening
Description: A specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The exercises are: short foot exercise, toe spread out, first toe extension, second to fifth toe extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles.
Study NCT05840965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foot orthotics
Description: Custom-made foot orthotics
Study NCT05513638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the clinical use of artificial intelligence in the diagnosis of prostate cancer
Description: Each study site will enroll consecutive eligible patients and randomize them to either (a) a group with human-based interpretation or (b) a group with human-artificial intelligence interactive interpretation, both of which are utilized as standards of care.
Study NCT06325995 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiation therapy
Description: 66-74 Gy in 33-37 daily fractions of 2 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
Study NCT06325995 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Description: 57.5-65 Gy in 23-26 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
Study NCT06063941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lugol's iodine solution
Description: 1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.
Study NCT06063941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Lugol's iodine solution
Description: Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.
Study NCT06192628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parkinson's Exercise and Education Programme
Description: A 12 week programme of exercise and education~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist only)
Study NCT06192628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parkinson's Exercise and Education Programme and Behavioural Change
Description: A 12-week programme of exercise, education and behavioural change techniques to support exercise adherence and exercise self-efficacy~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist and participant)~Additional techniques addressing behavioural regulation include firstly, an exercise diary completed independently at home, secondly, the rationale and the intended functional benefit and expectations of the exercise programme clearly explained, thirdly individual weekly conversations to reflect on progress, expectations, solutions to barriers, and goals. Finally, peer support is strongly encouraged through the in-class support, and a social media networking group.
Study NCT05212259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen type II (40 mg/day)
Description: 4 capsules per day
Study NCT05212259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen type II (80mg/day)
Description: 4 capsules per day
Study NCT05212259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen type II (120 mg/day)
Description: 4 capsules per day
Study NCT05212259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
Description: 4 capsules per day
Study NCT05212259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules per day
Study NCT06653686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with oral febuxostat.
Description: Extracorporeal high-frequency hyperthermia combined with oral febuxostat
Study NCT06653686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: The control group subjects were administered oral febuxostat.
Study NCT04375566 — intervention group
Intervention type: OTHER
Intervention: Patient Decision Aid
Description: More than 20 IT specialists, 15 doctors and 15 patients
Study NCT04886167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA
Description: Injection of platysmal bands.
Study NCT05628740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg NOC-100 (via nebulizer)
Description: Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
Study NCT05628740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 mg NOC-110 (via DPI) [1x 1 mg capsule]
Description: Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
Study NCT05628740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3 mg NOC-110 (via DPI)
Description: Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
Study NCT05628740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (via DPI)
Description: Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
Study NCT05628740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 6 mg NOC-110 (via DPI)
Description: Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule
Study NCT05628740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (via DPI) [2x Placebo capsules]
Description: Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
Study NCT04790903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will self-administer Venetoclax, as described in the Arm Descriptions.
Study NCT04790903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.
Study NCT04790903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive Rituximab at a dose of 375 mg/m\^2 by IV infusion on Day 1 of Cycles 1-6.
Study NCT04986059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-event massage
Description: Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
Study NCT05337059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP and Tidal Volume Titration
Description: PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures
Study NCT04790903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive Cyclophosphamide at a dose of 750 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
Study NCT05117827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Wheelchair Standing Device
Description: A power wheelchair standing device is a power wheelchair that allows a child to electronically move between sitting and standing. It can be driven in either position. The Permobil F5 Corpus VS is the specific power wheelchair standing device to be used in this study.
Study NCT04113252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Possible Incentive for Tablet Return
Description: Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
Study NCT04113252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive for Completed Diary
Description: Subjects who return completed diary will receive a gift card.
Study NCT04113252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Subjects will receive coaching prior to starting pain medication.
Study NCT05600400 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation
Description: 2 Fraction
Study NCT05600400 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Ablative Body Radiation
Description: 2 Fraction
Study NCT05018845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT05133648 — intervention group
Intervention type: PROCEDURE
Intervention: Hip Fracture Surgery
Description: Hip fracture surgery
Study NCT05133648 — intervention group
Intervention type: OTHER
Intervention: COVID-19 infection
Description: COVID-19 infection
Study NCT05251792 — intervention group
Intervention type: OTHER
Intervention: Ocular examination
Description: All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
Study NCT05005000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Micro-Fragmented Adipose Tissue (MFAT)
Description: 1ml of autologous micro-fragmented adipose tissue will be used.
Study NCT05005000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL
Description: The control group will receive a 1ml intraarticular injection of triamcinolone acetonide 10mg/ml.
Study NCT05058274 — intervention group
Intervention type: DEVICE
Intervention: Implant of the AT-TORBI 709 lens
Description: Implant of the AT-TORBI 709 lens
Study NCT05631756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: Evaluation of the Lung Ultrasound Score in patients presenting an interstitial syndrom on the lung ultrasound and to compare it with PaO2/FiO2
Study NCT05627440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Max Protein
Description: Ensure Max Protein, 1 bottle daily (330 mL), 30 grams protein
Study NCT05627440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Original
Description: Ensure Original, 1 bottle daily (237 mL), 9 grams protein
Study NCT05056246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maridebart cafraglutide
Description: Solution for injection
Study NCT05980013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole blood donation supine
Description: Subjects will undergo a 1-unit whole blood donation in a supine position
Study NCT05980013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole blood donation reclined
Description: Subjects will undergo a 1-unit whole blood donation in a reclined position
Study NCT05427149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)
Description: It will be evaluated whether there is postpinal shivering in the cases.
Study NCT05801978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Yellow Fever 17D Vaccine
Description: The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial. The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative. Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.
Study NCT05801978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine
Description: The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
Study NCT06309082 — intervention group
Intervention type: PROCEDURE
Intervention: Amputation
Description: Amputation was performed on diabetic foot ulcer
Study NCT06309082 — intervention group
Intervention type: PROCEDURE
Intervention: Debridement
Description: Debridement of diabetic foot ulcers was performed
Study NCT06250686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined exercise and nutrition intervention
Description: Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.
Study NCT05078723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limonene
Description: The investigators will ask the participants to swish 5 times and swallow 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract). The participant will be monitored for a total of 2 hours. Breath samples will be acquired at a total of 11 time points throughout the study. Measurements include 2 baseline measurements followed by the orange peel extract consumption.
Study NCT05112263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study
Study NCT05112263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: : Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight
Study NCT05325086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted information arm
Description: A adapted booklet will be delivered to patients at the start of the stay. This booklet contains adapted information about the pulmonary rehabilitation targetting the characteristics of the openness to experiences personality traits
Study NCT05325086 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral information arm
Description: A neutral booklet will be delivered to patients at the start of the stay. This booklet contains neutral information about the pulmonary rehabilitation
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Use according to the drug combination options selected by each center.
Study NCT04901117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Use according to the drug combination options selected by each center.